| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/13/2001 | US6201165 Drug screening by contacting isolated cardiomyocyte having calcineurin, calcium calmodulin dependent kinase iv or ii alpha, p38, or mkk6 transgene with compound; measuring physiological parameter; and comparing to control |
| 03/13/2001 | US6201115 Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications |
| 03/13/2001 | US6201111 Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors |
| 03/13/2001 | US6201108 Antibodies which bind to mammalian transforming growth factor-beta type ii receptor; treatment of bone disorders; anticarcinogenic/antimetastasis agents |
| 03/13/2001 | US6201105 Amino acid sequence; treatment of septic shock and cachexia; diagnosis |
| 03/13/2001 | US6201072 Block copolymers of polyether and polyester |
| 03/13/2001 | US6200959 Genetic induction of anti-viral immune response and genetic vaccine for filovirus |
| 03/13/2001 | US6200956 Nucleic acid-containing composition, preparation and use thereof |
| 03/13/2001 | US6200951 For detecting chitin, binding chitin, and treating fungal infections or for development of products useful for fungal infection therapy |
| 03/13/2001 | US6200787 Phenylalanyl tRNA synthetase polypeptides from streptococcus pneumoniae |
| 03/13/2001 | US6200780 Human interferon-ε(IFN-ε), a type I interferon |
| 03/13/2001 | US6200779 Nucleotide sequences which code protein associated with bacterial infection; for prevent of infections and associated defects |
| 03/13/2001 | US6200777 Human p101 polynucleotides |
| 03/13/2001 | US6200776 Polynucleotides encoding human sodium bicarbonate cotransporters |
| 03/13/2001 | US6200775 Nucleotide sequence coding a polypeptide associated with the diagnosis and treatment of infections |
| 03/13/2001 | US6200774 Compounds |
| 03/13/2001 | US6200768 Detecting compounds efficient in the dissolution of an alzheimer's protein; incubate preferential protein with kinase, monitor helix formation, incubate with modulator and detect blocking action by modulator |
| 03/13/2001 | US6200763 Detecting cell expressing myeloid polypeptide; incubate cell with binding substance and detecting bound substance, presence of bound protein indicates cell expressing myeloid protein |
| 03/13/2001 | US6200578 Genetic engineered polypeptide |
| 03/13/2001 | US6200575 These new ?inactivated? immunogens can be used to induce active immunization in humans which is capable of preventing or correcting the deregulatory effects which the native proteins from which they are produced may help to produce. |
| 03/13/2001 | US6200568 Composition and method of treating cancer with tannic acid and tannin complexes |
| 03/13/2001 | US6200567 An antibody that binds to the common beta c chain of the receptor for gm-csf, il-3 and il-5 |
| 03/13/2001 | US6200566 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| 03/13/2001 | US6200565 Oral administration of immunoglobulins for treating autoimmune hearing loss |
| 03/08/2001 | WO2001016377A2 Diagnostics and therapeutics for osteoporosis |
| 03/08/2001 | WO2001016344A1 Modified adenoviral fibre and uses thereof |
| 03/08/2001 | WO2001016343A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 03/08/2001 | WO2001016330A2 Prevention of affections associated with porcine circovirus-2 |
| 03/08/2001 | WO2001016326A2 Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate a |
| 03/08/2001 | WO2001016319A2 Compositions and methods for the treatment of immune related diseases |
| 03/08/2001 | WO2001016294A2 Metal binding compounds and their use in cell culture medium compositions |
| 03/08/2001 | WO2001016292A2 37 staphylococcus aureus genes and polypeptides |
| 03/08/2001 | WO2001016183A1 Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| 03/08/2001 | WO2001016174A2 Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65 |
| 03/08/2001 | WO2001016172A1 Vaccine antigens of moraxella |
| 03/08/2001 | WO2001016171A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 03/08/2001 | WO2001016170A2 Card proteins involved in cell death regulation |
| 03/08/2001 | WO2001016164A2 Treatment of allergic rhinitis |
| 03/08/2001 | WO2001016163A2 Peptide mixture and vaccine against a chronic viral infection |
| 03/08/2001 | WO2001016146A1 Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them |
| 03/08/2001 | WO2001015733A2 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 03/08/2001 | WO2001015732A1 Remedies for immunological diseases |
| 03/08/2001 | WO2001015731A1 Compositions and methods for the treatment of sepsis using antibodies to c5a |
| 03/08/2001 | WO2001015730A1 DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/08/2001 | WO2001015728A1 Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen |
| 03/08/2001 | WO2001015727A2 Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof |
| 03/08/2001 | WO2001015726A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | WO2001015725A1 Vaccine for the protection of a vertebrate animal against fungal skin infection |
| 03/08/2001 | WO2001015694A1 Extended duration light activated cancer therapy |
| 03/08/2001 | WO2001015666A1 Mixed micellar pharmaceutical delivery system and method of preparation |
| 03/08/2001 | WO2001015511A2 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| 03/08/2001 | WO2000069458A3 Adjuvant combinations for immunization composition and vaccines |
| 03/08/2001 | WO2000066735A3 Human ion channel proteins |
| 03/08/2001 | WO2000061766A3 Telomerase-specific cancer vaccine |
| 03/08/2001 | WO2000058475A3 Streptococcus pneumoniae antigens |
| 03/08/2001 | WO2000057861A3 Use of cytidine derivatives for the treatment of leukaemia |
| 03/08/2001 | WO2000039283A8 Use of cd40 engagement to alter t cell receptor usage |
| 03/08/2001 | WO2000038786A3 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 03/08/2001 | WO2000020447A8 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| 03/08/2001 | WO1999064047A8 Novel antiviral compounds |
| 03/08/2001 | DE19943702A1 New peptides that stimulate cytokine production in T cells, useful for vaccination against human cytomegalovirus infection and for detecting immune responses to the virus |
| 03/08/2001 | CA2388734A1 37 staphylococcus aureus genes and polypeptides |
| 03/08/2001 | CA2384055A1 Compositions and methods for the treatment of immune related diseases |
| 03/08/2001 | CA2383877A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 03/08/2001 | CA2383773A1 Methods and compositions for treating autoimmune disease |
| 03/08/2001 | CA2383693A1 Card proteins involved in cell death regulation |
| 03/08/2001 | CA2383557A1 Vaccine antigens of moraxella |
| 03/08/2001 | CA2383519A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 03/08/2001 | CA2383460A1 Metal binding compounds and their use in cell culture medium compositions |
| 03/08/2001 | CA2383367A1 Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
| 03/08/2001 | CA2382611A1 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | CA2382570A1 Treatment of allergic rhinitis |
| 03/08/2001 | CA2382345A1 Extended duration light activated cancer therapy |
| 03/08/2001 | CA2382100A1 Dosages for treatment with anti-erbb2 antibodies |
| 03/08/2001 | CA2348158A1 Modified adenoviral fibre and uses thereof |
| 03/07/2001 | EP1080371A1 Method and means for caries prevention and susceptibility detection |
| 03/07/2001 | EP1080370A1 Identification of broadly reactive dr restricted epitopes |
| 03/07/2001 | EP1080233A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
| 03/07/2001 | EP1080217A1 Recombinant cytomegalovirus expression system targeting the immediate-early gene region |
| 03/07/2001 | EP1080211A1 Method of producing thy-a-deficient strains of vibrio cholerae, such strains and their use |
| 03/07/2001 | EP1080206A1 Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiqitous endoproteases |
| 03/07/2001 | EP1080203A2 Human hydrolase homologs: n-terminal asparagine amidohydrolase, glycosyl hydrolase, glucohydrolase, biotinidase, and n-acetylglucosamine 6-p deacetylase |
| 03/07/2001 | EP1080201A2 Novel post-transcriptional regulatory elements and uses thereof |
| 03/07/2001 | EP1080200A1 Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4 |
| 03/07/2001 | EP1080199A2 (hemorrhagic enteritis) virus dna sequences, proteins encoded thereby and various uses thereof |
| 03/07/2001 | EP1080198A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 03/07/2001 | EP1080195A1 Endometriosis-associated gene |
| 03/07/2001 | EP1080185A2 Myelin basic protein peptides and uses thereof |
| 03/07/2001 | EP1080113A1 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| 03/07/2001 | EP1080110A2 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| 03/07/2001 | EP1080109A1 Method for purification of borrelia lipoprotein ospa |
| 03/07/2001 | EP1080107A2 Novel (poly)peptides which represent the epitopes of the human herpes virus type 8 |
| 03/07/2001 | EP1079875A2 Method and compositions for treatment of cancers |
| 03/07/2001 | EP1079862A1 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 03/07/2001 | EP1079860A1 Nicotine immunogen |
| 03/07/2001 | EP1079858A2 Oral immunization with papillomavirus virus-like particles |
| 03/07/2001 | EP1079857A1 Combination meningitidis b/c vaccines |
| 03/07/2001 | EP1079856A1 Humanized antibodies that recognize verotoxin ii and cell line producing same |
| 03/07/2001 | EP1079854A1 Compositions and methods of modulating an immune response to an antigen |
| 03/07/2001 | EP1079847A2 Osteoporosis treatment |